GSK/Prosensa at Cold Spring Harbor 2013

Much anticipated phase 2 data for the exon-skipping DMD drug drisapersen was presented at the Cold Spring Harbor RNA and Oligonucleotide conference in April 2013. This drug candidate is of course the major competitor to eteplirsen from SRPT (Sarepta Therapeutics). Many thanks to Adam Feuerstein of TheStreet.com for attending the event, reporting live, and giving permission to archive and share these slides here at BiotechDueDiligence.

Find additional coverage of the conference on the BDD blog.